ISIS-14803 Isis pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 2, Issue 11, 2001, Pages 1523-1529

  Witherell, G W ^a  

^a Questcor Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; INTERFERON; ISIS 14803; ISIS 6547; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DYSFUNCTION; LONG TERM CARE; NONHUMAN; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS; DRUG INDUSTRY; HEPATITIS C; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PHARMACEUTICAL PREPARATIONS;

EID: 0035182631     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes
2. Isis and Merck establish research collaboration for hepatitis C
3. Isis, Merck sign $50M deal for hepatitis C
4. Isis Pharmaceuticals Inc pipeline
5. Drug development pipeline: ISIS-14803 and VLA-4 theapeutic
6. Antisense oligonucleotides: Novel therapeutics for viral disease
7. Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides
8. Annual Report 1998 - Isis Pharmaceuticals Inc
9. Isis forms collaboration with Elan to develop antisense drug for hepatitis C
10. S-28463. Treatment of hepatic C interferon inducer
11. Isis reports year end and fourth quarter results for 1999
12. Isis receives fundamental patent of antisense technology
13. ISIS-14803 enters phase I/II human clinical trials for the treatment of hepatitis C
14. Isis Pharmaceuticals highlights new GeneTrove Functional Genomics Division at Cs First Boston West Coast Biotechnology Field Trip
15. Isis announces completion of $7.5 million financing with Elan
16. Praecis, Trimeris and Isis will announce news at TIDES 2000: IBC's Peptide and Oligonucleotide Technologies Conference
17. Annual Report 1999 - Isis Pharmaceuticals Inc
18. The disposition (ADME) of antisense oligonucleotides
19. Ibis Therapeutics and Agouron Pharmaceuticals Inc announce drug discovery collaboration
20. Inhibition of translation of hepatitis C virus RNA by 2′-modified antisense oligonucleotides
21. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
22. The delivery of antisense therapeutics
23. Isis Pharmaceuticals and Merck extend hepatitis C research collaboration
24. Antisense drug demonstrates substantial reduction of viral load in patients with drug resistant hepatitis C virus - Phase I/II study shows dose-dependent reduction of viral levels
25. Recent advances in prevention and treatment of hepatitis C virus infections
26. Molecular mechanisms of translation initiation in eukaryotes
27. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides
28. Internal ribosome entry sites in eukaryotic mRNA molecules
29. Compositions and methods for treatment of hepatitis C virus-associated diseases
30. Isis Pharmaceuticals reports third quarter 2001 highlights and financial results - Isis announces receipt of a DARPA contract for biological warfare defence and achievement of new milestones in two collaborations